达格列净联合二甲双胍治疗2型糖尿病的临床效果分析

目的观察不同药物方案治疗2型糖尿病(T2DM)的效果。方法选择2019年8月—2020年7月收治的128例T2DM患者,分为I、II组,均用二甲双胍治疗,II组联合达格列净,比较两组治疗情况。结果治疗后,II组FPG、2 hPG、HbAlc、HOMA-IR、FIns分别为(7.10±1.45)mmol/L、(8.12±1.95)mmol/L、(6.67±1.07)%、(3.01±1.09)、(14.31±3.55)mmol/L,和同期I组(9.12±1.54)mmol/L、(9.84±2.01)mmol/L、(8.03±1.42)%、(4.57±0.04)、(11.42±3.43)mmol/L,差异有统计学意义(t=3.284、4.257、3.257、3.875、4.527,P=0.040、0.037、0.041、0.039、0.035<0.05);I、II组不良反应发生率分别为12.50%、10.94%,差异无统计学意义(χ²=0.076,P=0.783>0.05)。结论采用达格列净与二甲双胍联合方案治疗T2DM,能更好的控制血糖水平,疗效确切,且安全性较高。

Analysis of the Clinical Effect of Dapagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes

Objective To observe the effects of different drug regimens in the treatment of type 2 diabetes(T2DM).Methods A total of 128 patients with T2DM admitted from August 2019 to July 2020 were divided into groups I and II,both of which were treated with metformin,and group II combined with dapagliflozin to compare the treatment of the two groups.Results After treatment,FPG,2 hPG,HbA1c,HOMA-IR and FIns in group II were(7.10±1.45)mmol/L,(8.12±1.95)mmol/L,(6.67±1.07)%,(3.01±1.09),(14.31±3.55)mmol/L,and the same period in group I(9.12±1.54)mmol/L,(9.84±2.01)mmol/L,(8.03±1.42)%,(4.57±0.04),(11.42±3.43)mmol/L,the difference was statistically significant(t=3.284,4.257,3.257,3.875,4.527,P=0.040,0.037,0.041,0.039,0.035<0.05);adverse reaction rates in groups I and II were 12.50%and 10.94%,respectively.The difference was not statistically significant(χ²=1.204,P=0.063>0.05).Conclusion The combined regimen of dapagliflozin and metformin in the treatment of T2DM can better control the blood glucose level,with definite curative effect and high safety.